El interés en corto de Genenta Science da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Genenta Science. Los datos de interés en corto se actualizan cada dos semanas.

Genenta Science (NASDAQ:GNTA) Bolsa, Informe de interés en corto

Genenta Science

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

Genenta Science S.p.A. - American Depositary Shares

Genenta Science SPA

News

ACIW

ACI Worldwide To Protect Zimbabwe's Payments Landscape Through Partnership With Zimswitch

<p><strong>Third Quarter 2024 Operational Highlights</strong></p>
<ul>
<li><strong>Total number of paying clients</strong>1 increased 33.1% year-over-year to 2,196,647 as of September 30, 2024.</li>
<li><strong>Total number of registered clients</strong>2 increased 22.8% year-over-year to 4,284,786 as of September 30, 2024.</li>
<li><strong>Total number of users</strong>3 increased 14.4% year-over-year to 24.1 million as of September 30, 2024.</li>
<li><strong>Total client assets </strong>increased 48.1% year-over-year to HK$693.4 billion as of September 30, 2024.</li>
<li><strong>Daily average client assets </strong>were HK$593.2 billion in the third quarter of 2024, an increase of 23.4% from the same period in 2023.</li>
<li><strong>Total trading volume in the third quarter of 2024 </strong>increased by 74.7% year-over-year to HK$1.90 trillion, in which trading volume for U.S. stocks was HK$1.53 trillion, and trading volume for Hong Kong stocks was HK$347.7 billion.</li>
<li><strong>Daily average revenue trades (DARTs)</strong>4<strong> in the third quarter of 2024 </strong>increased 68.0% year-over-year to 698,811.</li>
<li><strong>Margin financing and securities lending balance</strong> increased 25.5% year-over-year to HK$40.6 billion as of September 30, 2024.</li>
</ul>


Earnings

FUTU

FUTU's Q3 Total Number Of Paying Clients Increased 33.1% YoY; Total Number Of Users +14.4%YoY; Total Client Assets +48.1% YoY; Total Trading Volume +74.7% YoY

<p><strong>Lowe&#8217;s Companies, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/LOW/earnings">opening bell on Tuesday, Nov. 19.</a></p>
<p>Analysts expect the Mooresville, North Carolina-based company to report quarterly earnings at $2.81 per share, down from $3.06 per share in the year-ago period. Lowe&#8217;s projects to report quarterly revenue of $19.91 billion, compared to $20.47 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.</p>
<p>On Aug. 20, the company reported adjusted earnings per share of $4.10, beating the analyst consensus of $3.99. Quarterly revenues totaled $23.586 billion, missing the street view of $24.013 billion.</p>
<p>Lowe&#8217;s shares gained 0.9% to close at $271.77 on Monday.</p>
<p>Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>
<p>Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">analysts have rated the company</a> in the recent period.</p>
<ul>
<li>Telsey Advisory Group analyst Joseph Feldman upgraded the stock from Market Perform to Outperform and raised the price target from $275 to $305 on Nov. 8. This analyst has an accuracy rate of 69%.</li>
<li>Truist Securities analyst Scot Ciccarelli maintained a Buy rating and increased the price target from $306 to $307 on Nov. 7. This analyst has an accuracy rate of 75%.</li>
<li>Wells Fargo analyst Zachary Fadem maintained an Overweight rating and raised the price target from $280 to $295 on Nov. 6. This analyst has an accuracy rate of 87%.</li>
<li>TD Cowen analyst Max Rakhlenko maintained a Hold rating and boosted the price target from $270 to $290 on Oct. 28. This analyst has an accuracy rate of 61%.</li>
<li>Loop Capital analyst Laura Champine upgraded the stock from Hold to Buy and increased the price target from $250 to $300 on Oct. 9. This analyst has an accuracy rate of 64%.</li>
</ul>
<p>Considering buying LOW stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19020841/image-185-1024x559.png" alt="" class="wp-image-654276" style="width:626px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19020841/image-185-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19020841/image-185-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19020841/image-185-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19020841/image-185.png 1222w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></strong></li>
</ul>


Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Lowe's Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<p>Futu Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) reported quarterly earnings of HK$9.42 per share which missed the analyst consensus estimate of HK$9.85 by 4.37 percent. This is a 19.85 percent increase over earnings of HK$7.86 per share from the same period last year. The company reported quarterly sales of HK$3.436 billion which beat the analyst consensus estimate of HK$3.209 billion by 7.07 percent. This is a 29.66 percent increase over sales of HK$2.650 billion the same period last year.</p>


Earnings Beats

Earnings Misses

Futu Holdings Q3 2024 Adj. EPS HK$9.42 Misses HK$9.85 Estimate, Sales HK$3.436B Beat HK$3.209B Estimate

<p>Rapper <strong>Heather Morgan</strong>, known as the &#8216;Crocodile of Wall Street&#8217;, is set to serve 18 months in prison for conspiring with her hacker husband to launder billions of dollars of stolen <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).</p>
<p><strong>What Happened</strong>: Morgan, 34, was sentenced on Monday in a federal court in Washington for her role in the sensational cyberattack on cryptocurrency exchange&nbsp;<strong>Bitfinex </strong>in 2016, according to a <a href="https://www.bloomberg.com/news/articles/2024-11-18/hacker-s-wife-razzlekhan-gets-18-months-for-money-laundering">report </a>by Bloomberg. Her spouse and hack mastermind, <strong>Ilya Lichtenstein</strong>, has already been awarded a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011697/bitcoin-hacker-sentenced-to-5-years-for-laundering-billions-in-crypto-theft">five-year sentence</a>. </p>
<p><strong>See Also: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42053981/trump-sec-pick-speculation-sends-this-altcoin-soaring-past-bitcoin-and-ethereum-in-daily-gains">Trump SEC Pick Speculation Sends This Altcoin Soaring Past Bitcoin And Ethereum In Daily Gains</a></strong></p>
<p>Morgan became a well-known figure in Twitter's (now X) high-finance community for posting obscure rap videos under the moniker &#8220;The Crocodile of Wall Street.&#8221;</p>
<p><strong>Why It Matters</strong>: Morgan and Lichtenstein were <a href="https://www.benzinga.com/markets/cryptocurrency/23/01/30468047/from-wall-street-to-tech-company-hire-the-story-of-the-crocodile-and-the-120-000-bitcoin-h">charged</a> by the Justice Department in February 2022 in what has been described by authorities as one of the most sophisticated money-laundering operations ever encountered in the cryptocurrency space.</p>
<p>The hack targeted Hong Kong-based exchange Bitfinex in 2016, compromising 36% of the company&#8217;s assets. About 119,754 BTCs were stolen in the attack, worth about $71 million at that time and over $11 billion today. By 2022, the couple had successfully laundered around 21% of the stolen funds, worth $14 million at 2016 prices and exceeding $1 billion in 2022.</p>
<p>Authorities recovered over 96% of the stolen Bitcoin, valued at over $6 billion, thanks in part to Lichtenstein&#8217;s cooperation following his arrest in 2022.</p>
<p>Last year, the couple <a href="https://www.benzinga.com/markets/cryptocurrency/23/08/33566259/razzlekhan-and-husband-plead-guilty-in-multibillion-dollar-bitcoin-laundering-case">pleaded guilty</a> to charges. Morgan, who was not part of the original hack, was enlisted by Lichtenstein to launder the stolen digital currency.</p>
<p><strong>Price Action</strong>: At the time of writing, Bitcoin was trading at $91,943.90, up 0.84% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.</p>
<p><em>Photo Courtesy: Shutterstock.com</em></p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42052797/trump-and-coinbase-ceo-brian-armstrong-reportedly-in-talks-over-cabinet-appointments">Trump And Coinbase CEO Brian Armstrong Reportedly In Talks Over Cabinet Appointments</a></strong></li>
</ul>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitfinex Bitcoin Laundering Case Lands 'Crocodile Of Wall Street' In Jail

<p>BW LPG is pleased to announce that its 52% owned subsidiary BW LPG India has decided to sell its 2007-built vessel BW Cedar as part of a planned fleet renewal. On a 100% basis, the sale is priced at approximately US$65 million and is expected to generate a net book gain of around US$33 million and about US$51 million in net cash after repayment of its existing bank loan. The vessel will be delivered to the new owners in Q1 2025.</p>
<p>In addition, BW LPG has declared a purchase option for BW Kizoku, a 2019 Japan-built VLGC. BW Kizoku is currently on time charter with BW LPG with a purchase option, which BW LPG exercised for a consideration of US$69.8 million. The vessel is expected to be delivered in January 2025 and will continue to trade in the conventional BW LPG fleet.</p>


BWLP

BW LPG Sells 2007-Built BW Cedar For $65M, Acquires Modern 2019-Built BW Kizoku For $69.8M

<ul>
<li>Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics</li>
<li>Up to €490 Million in Commercial Milestone Payments, with</li>
<li>Tiered Royalties on Future Sales</li>
</ul>


BAYRY

CYTK

Cytokinetics And Bayer Partner For Exclusive Development And Commercialization Of Aficamten In Japan

<ul>
<li>EPIC Advanced Packaging marks an expansion of Applied's global innovation platform</li>
<li>Company convenes top semiconductor R&amp;D leaders to advance high-performance, low-power AI chip packaging technologies</li>
</ul>


AMAT

Applied Materials Expands Global Innovation Platform With Advanced Packaging Collaboration For AI Era

<p>Proceeds to be used primarily to acquire bitcoin and repurchase existing convertible notes due 2026</p>


MARA

Reported Earlier, MARA Holdings Prices $850M Oversubscribed And Upsized Zero-Coupon Convertible Notes Offering Due 2030

<p><i>Hyperlux advanced imaging capabilities capture most accurate visual data to ensure error-free interpretation of driving environments and enhance car safety</i>&nbsp;</p>
<p><strong>NEWS HIGHLIGHTS</strong></p>
<ul>
<li>onsemi will be the primary supplier of image sensors for Subaru's next-generation EyeSight stereo-camera front sensing system</li>
<li>Hyperlux image sensors feature whole pixel design and High Dynamic Range to significantly improve image clarity and accuracy</li>
<li>Equipped with functional safety features, Hyperlux sensors ensure greater level of safety and reliability of the system</li>
<li>Selection follows longstanding collaboration between companies to improve vehicle safety by tailoring sensors to multiple generations of Subaru's stereo-camera front sensing system</li>
</ul>


Reported Earlier, Subaru Selects onsemi Hyperlux Sensors To Enhance AI-Integrated EyeSight Driver Assistance System

<p>Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –</p>
<p>– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –</p>
<p>– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –</p>
<p>– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –</p>


Reported Earlier, Vir Biotechnology Announces Phase 2 Data And Phase 3 Launch For Chronic Hepatitis Delta Treatment

SYRE

Reported Earlier, Spyre Therapeutics Prices $200M Public Offering Of 7.275M Common Shares At $27.50/Share

<p>The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $6.9 million before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on or about November 20, 2024, subject to the satisfaction of customary closing conditions.</p>


HCWB

Reported Earlier, HCW Biologics Announces $6.9M Direct Offering And Private Placement Priced Above Market

<p>Select intends to use the net proceeds of the Offering, together with the proceeds from the proposed new incremental term loan and cash on hand, to repay in full the term loans currently outstanding under Select's existing senior secured credit agreement, to redeem all of Select's outstanding 6.250% senior notes due 2026 and to pay fees and expenses related to the foregoing.&nbsp;</p>


Reported Earlier, Select Medical Announces Pricing of $550M 6.250% Senior Notes Due 2032

<p>The fundamentals of our business are strong. Our AirSCWO technology is performing well across biosolid/sludge and liquid waste streams. Our DaaS business is taking shape representing near-term recurring revenue, with our first operating site being actively negotiated to destroy non-hazardous waste, and our conversations are advancing with TSDF operators for onsite non-hazardous and hazardous waste destruction. Our approach to opening markets is bearing fruit with opportunities across AFFF, GAC, IX, and other organic waste streams. Our current backlog/pipeline exceeds $1.8B and we believe this will grow further.</p>


SCWO

Reported Earlier, 374Water Highlights Commercial Milestones, $1.8B Pipeline, And Growing Opportunities In Waste Management

<p>Telix's development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and prostate cancers.</p>
<p>FAP is a pan-cancer marker expressed in the tumor microenvironment of epithelial cancers and on the surface of some specific cancer types, including sarcomas and mesotheliomas.</p>


Reported Earlier, Telix Expands Theranostic Pipeline With FAP-Targeting Radiopharmaceuticals For Pan-Cancer Treatment

<p>The Company stated that while its financial position remains sound, the Board of Directors determined that the reduction in the dividend was prudent given the Company's recent operating performance. As previously disclosed, the Company has been implementing multiple initiatives to improve performance that have led to year-over-year performance improvement. These include price adjustments with our customers and cost reduction projects, including the previously disclosed consolidation of the&nbsp;Albia, Iowa operation into the Tyrone, Pennsylvania operation.</p>


Reported Earlier, Chicago Rivet & Machine Reduces Quarterly Dividend To $0.03 Per Share From $0.10 Per Share, Payable December 20, 2024

ZENV

Reported Earlier, Zenvia Q3 Sales R$284.400M Beat R$249.810M Estimate; Net Income R$52.62M Up From Net loss R$11.94M

ZEPP

Reported Earlier, Zepp Health Q3 EPS $(0.78) Down From $0.12 YoY, Sales $42.50M Down From $82.53M YoY

<ul>
<li>IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL</li>
<li>IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients</li>
<li>In vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to migrate and infiltrate tumors</li>
<li>Results support clinical development of IPH6501 in R/R B-NHL</li>
</ul>


IPHA

Innate Pharma Publishes Preclinical Data Demonstrating The Potential Of IPH6501 In Science Immunology

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA invites its shareholders to the upcoming ordinary and extraord...

Genenta Science Announces Shareholder Meeting

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science's CEO Pierluigi Paracchi has proposed a new slate of candidates fo...

Genenta Science Announces Board Restructuring

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, an Italian biotech firm, has entered into an agreement with V...

Genenta Science Announces ADS Sales Agreement

Genenta Science SpA Sponsored ADR (GNTA) has released an update. Genenta Science SpA, a biotech company based in Milan, is focused on the research,...

Genenta Science Advances Biotech Endeavors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cingulate Inc (CING – Research Report) and Genenta...

Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;</p>



<p>Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.</p>



<p>Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.</p>



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p><strong>FibroGen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fgen-stock-quote/"><strong>FGEN</strong></a></span>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.</p>



<p>Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;</p>



<p>One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.</p>



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p><strong>Nuvectis Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvct-stock-quote/"><strong>NVCT</strong></a></span>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.</p>



<p>Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;</p>



<p>The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.</p>



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Relmada Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/"><strong>RLMD</strong></a></span>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.</p>



<p>REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.</p>



<p>The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;</p>



<p>Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.</p>



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div><p><strong>Anixa Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/anix-stock-quote/"><strong>ANIX</strong></a></span>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;</p>



<p>The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;</p>



<p>The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.</p>



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div><p>Let&rsquo;s begin discussing<strong> Genenta Science</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gnta-stock-quote/"><strong>GNTA</strong></a></span>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.</p>



<p>While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.</p>



<p>The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;</p>



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div><p><strong>Affimed</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/afmd-stock-quote/"><strong>AFMD</strong></a></span>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.</p>



<p>The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.</p>



<p>AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;</p>



<p>As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;</p>



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Lipocine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/"><strong>LPCN</strong></a></span>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.</p>



<p>As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.</p>



<p>However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;</p>



<p>What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.</p>



<p><em><strong>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks</strong>: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More</strong>: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a></em></p>



<p><em>On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> Publishing Guidelines.</em></a></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Penny Biotech Stocks to Triple Your Investment

Maxim Group analyst Jason McCarthy maintained a Buy rating on Genenta Science SpA Sponsored ADR (GNTA – Research Report) yesterday and set a price ...

Buy Rating Affirmed for Genenta Science Amid Promising Developments in Gene Therapy Trials

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR – Research Report) and Genenta Science SpA Sponsored...

Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Genenta Science SpA Sponsored ADR (GNTA)

09:35 EDT Genenta Science (GNTA) SPA (ADR) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

Genenta Science SPA (ADR) trading resumes

Genenta Science (GNTA) announced that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting "Cross-Border Investments and Str...

Genenta Science CEO to present at U.S. Senate meeting

AFMD

ANIX

CING

FGEN

GNTA

LPCN

NVCT

RLMD

Health Care

Press Releases

General

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Management

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"

Comments

Genenta Science

Interés en corto

Genenta Science (NASDAQ:GNTA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL